

PATENT CASE CVE 48

Examiner: To Be Assigned

## IN THE UNITED STATES PATENT AND TRADEMARK OFFIC

In re Application of:

Harry R. Davis et al

For Patent For:

Combinations of Peroxisome Proliferator-

Activated Receptor (PPAR) Activator(s) and Sterol Absorption Inhibitor(s) and

Treatments for Vascular Indications

Serial No.: 10/057,323

Filing Date: January 25, 2002

Schering-Plough Corporation Kenilworth, New Jersey 07033-0530

Art Unit: 1619

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants respectfully request that the documents listed on the accompanying PTO-1449 Form be considered and made of record.

Applicant has enclosed a complete PTO-1449 Form with this submission.

The Examiner is respectfully requested to examine this publication, to initial the form PTO-1449 and to return a copy of the initialed form to applicants.

The Commissioner is authorized to charge Deposit Account No. 19-0365 for any additional fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Respecfully submitted,

on <u>May 5, 2003</u>

Ann Marie Cannoni

Registered Representative

Signature

15/03

Ann Marie Cannoni

Reg. No. 35,972

Attorney for Applicants

(908) 298-5024

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if nee

ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/057,323	
APPLICANT:		
Harry R. Davis et al.		

	, , , , , , , , , , , , , , , , , , , ,		
cessary)	FILING DATE: January 25, 2002	GROUP:1617 1619	
			_

			U.S. F	PATENT	DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS		FILING	DATE IF
MALIAL	AA	NOMBER					CLAS	APPR(	OPRIATE
	AB		+	<del> </del>			<u> </u>		
	AC		+				( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )	14	<u> </u>
	AD		<del> </del>				7/		1/2-
	AE		+	+			1	90	<b>A</b>
	AF		<del>                                     </del>	+			1	1 300	
	AG						\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\		,
	AH			<del>†</del>				<del>%</del>	
	ΑI			<del> </del>			<del> </del>	1000	
	AJ						<del>                                     </del>	1 90	2
	AK						<del>                                      </del>	<del>                                     </del>	
				N PATE	NT DOCUMENT	S	<u> </u>		
		DOCUMENT	DATE	COUNT	RY	CLASS	SUB-	TRANS	LATION
		NUMBER					CLASS	YES	NO
	AL								
	AM			<u> </u>					
	AN		<del> </del>	ļ					
	AO AP		<del> </del>						
			L						
	OTI	HER DOCUMENT	TS (Includ	dina Aut	hor Title Date	Pertinent Pa	nes Et	<u> </u>	
	AQ	Luis Gruberg, MD, I (CRP) and Chlamyo	ntiammator	∿ Marker	s in Acute Coronary	Syndromes	-reactive	Proteir	1,
	AR	<u> </u>	, 7 11101100	arr reart 7	ASSOCIATION SCIENTIN	C Sessions 200	<u> </u>		
	AS			_		·			
	AT								
	AU								
	ΑV								
XAMINER					DATE CONSIDER	ED	<del></del>		-
					· - · - · · · · · · · · · · · ·	<del></del>			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.